$CGTX
COGNITION THERAPEUTICS INC

2023 Q4 Form 10-Q Financial Statement

#000155837023017321 Filed on November 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.589M $3.080M
YoY Change 25.49% -29.31%
% of Gross Profit
Research & Development $11.60M $11.67M
YoY Change 80.12% 41.13%
% of Gross Profit
Depreciation & Amortization $26.00K $30.00K
YoY Change 13.04% 36.36%
% of Gross Profit
Operating Expenses $15.19M $14.75M
YoY Change 63.32% 16.79%
Operating Profit -$14.75M
YoY Change 16.79%
Interest Expense -$9.000K $0.00
YoY Change -10.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $7.057M $7.996M
YoY Change 70.95% 33.27%
Pretax Income -$8.141M -$6.750M
YoY Change 57.1% 1.89%
Income Tax
% Of Pretax Income
Net Earnings -$8.141M -$6.749M
YoY Change 57.1% 1.87%
Net Earnings / Revenue
Basic Earnings Per Share -$0.22
Diluted Earnings Per Share -$0.26 -$0.22
COMMON SHARES
Basic Shares Outstanding 30.42M 30.31M
Diluted Shares Outstanding 30.37M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $29.92M $32.97M
YoY Change -28.01% -29.26%
Cash & Equivalents $29.92M $32.97M
Short-Term Investments
Other Short-Term Assets $3.019M $1.430M
YoY Change 25.11% -20.29%
Inventory
Prepaid Expenses $3.019M $1.433M
Receivables
Other Receivables
Total Short-Term Assets $34.22M $36.04M
YoY Change -28.18% -29.24%
LONG-TERM ASSETS
Property, Plant & Equipment $941.0K $281.0K
YoY Change 303.86% 14.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $1.760M
YoY Change -100.0% 4.27%
Total Long-Term Assets $941.0K $2.732M
YoY Change -66.13% 4.08%
TOTAL ASSETS
Total Short-Term Assets $34.22M $36.04M
Total Long-Term Assets $941.0K $2.732M
Total Assets $35.16M $38.77M
YoY Change -30.27% -27.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.695M $2.859M
YoY Change 14.89% -64.65%
Accrued Expenses $4.229M $4.288M
YoY Change 101.96% 85.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.17M $8.229M
YoY Change 30.46% -32.08%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $520.0K $1.052M
YoY Change -69.16% -30.7%
Total Long-Term Liabilities $520.0K $1.052M
YoY Change -69.16% -30.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.17M $8.229M
Total Long-Term Liabilities $520.0K $1.052M
Total Liabilities $10.69M $9.846M
YoY Change 5.04% -30.84%
SHAREHOLDERS EQUITY
Retained Earnings -$141.2M -$133.0M
YoY Change 22.35% 20.71%
Common Stock $32.00K $30.00K
YoY Change 10.34% 25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $24.47M $28.93M
YoY Change
Total Liabilities & Shareholders Equity $35.16M $38.77M
YoY Change -30.27% -27.61%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$8.141M -$6.749M
YoY Change 57.1% 1.87%
Depreciation, Depletion And Amortization $26.00K $30.00K
YoY Change 13.04% 36.36%
Cash From Operating Activities -$5.458M -$4.160M
YoY Change -46.41% 103900.0%
INVESTING ACTIVITIES
Capital Expenditures $27.00K $60.00K
YoY Change 170.0% -360.87%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$27.00K -$60.00K
YoY Change 170.0% 160.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.441M -10.00K
YoY Change -52.53% -101.15%
NET CHANGE
Cash From Operating Activities -5.458M -4.160M
Cash From Investing Activities -27.00K -60.00K
Cash From Financing Activities 2.441M -10.00K
Net Change In Cash -3.044M -4.230M
YoY Change -39.75% -602.38%
FREE CASH FLOW
Cash From Operating Activities -$5.458M -$4.160M
Capital Expenditures $27.00K $60.00K
Free Cash Flow -$5.485M -$4.220M
YoY Change -46.19% -22310.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001455365
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28991548
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30417082
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40886
dei Entity Registrant Name
EntityRegistrantName
Cognition Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-4365359
dei Entity Address Address Line1
EntityAddressAddressLine1
2500 Westchester Ave.
dei Entity Address City Or Town
EntityAddressCityOrTown
Purchase
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10577
dei City Area Code
CityAreaCode
412
dei Local Phone Number
LocalPhoneNumber
481-2210
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CGTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30417082
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32969000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41562000
CY2023Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1638000
CY2022Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
3672000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1433000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2413000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
36040000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
47647000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
281000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
233000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
696000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
813000
CY2023Q3 us-gaap Other Assets
OtherAssets
1755000
CY2022Q4 us-gaap Other Assets
OtherAssets
1732000
CY2023Q3 us-gaap Assets
Assets
38772000
CY2022Q4 us-gaap Assets
Assets
50425000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2859000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3216000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4288000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2094000
CY2023Q3 cgtx Deferred Grant Income Current
DeferredGrantIncomeCurrent
910000
CY2022Q4 cgtx Deferred Grant Income Current
DeferredGrantIncomeCurrent
1702000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
170000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
149000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
634000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8229000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7795000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
565000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
695000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1052000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1686000
CY2023Q3 us-gaap Liabilities
Liabilities
9846000
CY2022Q4 us-gaap Liabilities
Liabilities
10176000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30417082
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28991548
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
30000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
29000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
162140000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
155820000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-133048000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-115401000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-196000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-199000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
28926000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
40249000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38772000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50425000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11669000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8268000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25596000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23884000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3076000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4357000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9939000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10367000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
14745000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
12625000
us-gaap Operating Expenses
OperatingExpenses
35535000
us-gaap Operating Expenses
OperatingExpenses
34251000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14745000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12625000
us-gaap Operating Income Loss
OperatingIncomeLoss
-35535000
us-gaap Operating Income Loss
OperatingIncomeLoss
-34251000
CY2023Q3 cgtx Grant Income
GrantIncome
7684000
CY2022Q3 cgtx Grant Income
GrantIncome
5947000
cgtx Grant Income
GrantIncome
18035000
cgtx Grant Income
GrantIncome
18236000
CY2023Q3 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
314000
CY2022Q3 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
55000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-129000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-182000
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-2000
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-2000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-18000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-18000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7996000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17888000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
18036000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6749000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6625000
us-gaap Net Income Loss
NetIncomeLoss
-17647000
us-gaap Net Income Loss
NetIncomeLoss
-16215000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6749000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6626000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17644000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16218000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30365506
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23024026
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29696296
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22684309
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30365506
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23024026
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29696296
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22684309
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
40249000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1187000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6172000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
35783000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2305000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1025000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4726000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
34386000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1071000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6749000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
28926000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
51273000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
303000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1001000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3838000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
48740000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
22000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
892000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5752000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
43899000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1270000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
777000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6625000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
39320000
us-gaap Net Income Loss
NetIncomeLoss
-17647000
us-gaap Net Income Loss
NetIncomeLoss
-16215000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
69000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
60000
us-gaap Share Based Compensation
ShareBasedCompensation
3283000
us-gaap Share Based Compensation
ShareBasedCompensation
2670000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
117000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
115000
cgtx Issuance Of Common Stock As Commitment Shares For Equity Line Financing
IssuanceOfCommonStockAsCommitmentSharesForEquityLineFinancing
318000
cgtx Gain Loss On Sale Of Common Stock Pursuant To Purchase Agreement
GainLossOnSaleOfCommonStockPursuantToPurchaseAgreement
-5000
cgtx Increase Decrease In Grant Receivables
IncreaseDecreaseInGrantReceivables
-2034000
cgtx Increase Decrease In Grant Receivables
IncreaseDecreaseInGrantReceivables
727000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-957000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1477000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-465000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1837000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4482000
cgtx Increase Decrease In Deferred Grant Income Current
IncreaseDecreaseInDeferredGrantIncomeCurrent
-1426000
cgtx Increase Decrease In Deferred Grant Income Current
IncreaseDecreaseInDeferredGrantIncomeCurrent
2366000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-109000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-88000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10562000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8349000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
117000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
161000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-117000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-161000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1595000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
632000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
1191000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2082000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
404000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-5000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8593000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8111000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41562000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54721000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32969000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46610000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
189000
CY2022Q4 cgtx Maximum Aggregate Offering Price
MaximumAggregateOfferingPrice
200000000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32969000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
37479000
CY2023Q3 cgtx Allowance For Credit Loss Grants Receivable Current
AllowanceForCreditLossGrantsReceivableCurrent
0
CY2023Q3 cgtx Grant Income
GrantIncome
7684000
cgtx Grant Income
GrantIncome
18035000
CY2022Q3 cgtx Grant Income
GrantIncome
5947000
cgtx Grant Income
GrantIncome
18236000
CY2023Q3 cgtx Deferred Grant Income Current
DeferredGrantIncomeCurrent
910000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1052000
CY2022Q4 cgtx Deferred Grant Income Current
DeferredGrantIncomeCurrent
1702000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1686000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company’s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
32558000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
919000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
870000
CY2023Q3 cgtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
3231000
CY2022Q4 cgtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
900000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
138000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
324000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4288000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2094000
CY2023Q3 cgtx Operating Lease Assets
OperatingLeaseAssets
696000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
696000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
170000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
565000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
735000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
53000
us-gaap Operating Lease Expense
OperatingLeaseExpense
161000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
50000
us-gaap Operating Lease Expense
OperatingLeaseExpense
149000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9272
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0346
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0426
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0187
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0340
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
55000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
221000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
222000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
154000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
87000
CY2023Q3 cgtx Lessee Operating Lease Liability To Be Paid After Year Three
LesseeOperatingLeaseLiabilityToBePaidAfterYearThree
125000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
864000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
129000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
735000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.081
us-gaap Operating Lease Payments
OperatingLeasePayments
154000
us-gaap Operating Lease Payments
OperatingLeasePayments
123000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Dividends Common Stock
DividendsCommonStock
0
cgtx Remaining Value Of Stock To Be Issued Under Agreement
RemainingValueOfStockToBeIssuedUnderAgreement
34795000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9153
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9268
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9109
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3679468
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.13
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2085000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
595769
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
79742
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.95
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
10901
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
2.10
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4184594
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.76
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
740000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2838915
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.91
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
687000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M24D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.59
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.47
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.90
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
19500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
595769
CY2023Q3 cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
24000
cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
950000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
14000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
449270
CY2022Q3 cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
21000
cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
838000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2023Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1371589
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1739465
CY2022Q3 cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue
1018000
cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue
1308000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1596000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2717000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1071000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
777000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3283000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2670000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
5306000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M8D
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4707188
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3733446

Files In Submission

Name View Source Status
0001558370-23-017321-index-headers.html Edgar Link pending
0001558370-23-017321-index.html Edgar Link pending
0001558370-23-017321.txt Edgar Link pending
0001558370-23-017321-xbrl.zip Edgar Link pending
cgtx-20230930.xsd Edgar Link pending
cgtx-20230930x10q.htm Edgar Link pending
cgtx-20230930xex31d1.htm Edgar Link pending
cgtx-20230930xex31d2.htm Edgar Link pending
cgtx-20230930xex32d1.htm Edgar Link pending
cgtx-20230930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
cgtx-20230930_cal.xml Edgar Link unprocessable
cgtx-20230930_def.xml Edgar Link unprocessable
cgtx-20230930_pre.xml Edgar Link unprocessable
cgtx-20230930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cgtx-20230930x10q_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending